Weidong Xiao, PhD

 Vice President

Founder and CEO of Nikegen, Professor at Indiana University, interested in molecular virology, development of vectors for gene therapy, and treatment of hemophilia. Graduated from University of North Carolina-Chapel Hill

 Zuyi Huang, PhD

Vice President

Associate Professor at Villanova University, interested in systems biology, drug discovery, gene and cell therapy. Graduated from Tsinghua University and Texas A&M University

Yanming Du, PhD

Vice President

Professor and Director of Medicinal Chemistry at Baruch S. Blumberg Institute (BSBI), expertise in medicinal chemistry for infectious diseases, graduated from Jilin University, Wuhan University, and University of Iowa

Ju-Tao Guo, PhD

Vice president

Thomas London Distinguished Professor; Chair, and Vice President at Baruch S. Blumberg Institute (BSBI). Graduated from Peking Union Medical College (PUMC), and Lanzhou University

Mingjing Zhou, PhD

Vice President

CEO & Co-Founder of Genemagic Biosciences, interested in neural regeneration to cure patients with CNS diseases. Graduated from Peking University

Shuibing Chen, PhD

Vice President

The Kilts Family Professor, the Director of the Diabetes Program, and Vice Chair of Innovation at the Department of Surgery, Director of the Center of Genomic Health at Weill Cornell Medicine, interested in human pluripotent stem cell-derived organoids for disease modeling and drug screening. Graduated from the Scripps Research Institute and Tsinghua University

Yaling Liu, PhD

Vice President

Professor and Director of Graduate Studies of Bioengineering at Lehigh University, interested in organ-on-chip and precision medicine. Graduated from Tsinghua University and Northwestern University.

Jinglin Fu, PhD

Vice President

Associate Professor at Rutgers University-Camden, interested in nucleic acids technology, drug delivery, bionanomaterials and biotechnology. Graduated from Zhejiang University and Arizona State University.

Weifeng Xu, PhD

Vice President

Director, leading Cell Assay Group at Preclinical Development, Regulated Bioanalytics, Merck. Weifeng has been in the field of immunogenicity for more than 10 years, with multiple patents as well as co-editor of a book in the field, supported dozens of biotherapeutics. Graduated from Chinese Academy of Science.

Jinhong Chang, MD, PhD

Vice President

Professor and Principal Investigator at Baruch S. Blumberg Institute (BSBI), interested in molecular virology, innate immunity, and antiviral drug discovery. Graduated from Peking University

Guosheng Wu, PhD

Vice President

Vice-President of Computational Drug Discovery at Pharmaron. Graduated from Northwestern University

Jun Wang, PhD

Vice President

Associate Professor and Director of Medicinal Chemistry graduate program at the Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, interested in antiviral drug discovery, drug resistance, and target validation. Graduated from Wuhan University and the University of Pennsylvania.

Richard Huang, PhD

Director

CMC program management at Alexion. Graduated from Rensselaer Polytechnic Institute

Zhongmin Alex Ma, PhD

Vice President

Founder and CEO of Revivallon, former professor at Mount Sinai School of Medicine, interested in pancreatic β-cell regeneration and drug development to treat diabetes. Graduated from Fudan University and St. Louis University.

Yi Zhu, MD, MBA

Vice President

Vice President of Global Clinical Development and Clinical Operations at Ionova Life Sciences. 25+ years clinical research experiences, R&D management, and commercial management experiences in academic institutes; pharmaceutical Industry, Biotech Industry as well as in CRO business. Graduated from Chongqing University of Medical Sciences, University of Pennsylvania, and University of Delaware

Xiaoqing Zhang, MD, PhD, MBA, PhD

Vice President

Sr. Clinical Trial Physician, Global Drug Development, Bristol Myers Squibb. Interested in oncology clinical development strategy and planning, study design from FIH to registrational trials, due diligence for BD projects, etc. Graduated from Shanghai Jiaotong University and Upenn Wharton School of Business.

Daniel Zhu, MD, PhD

Vice President

Senior Clinical Trial Physician at BMS, worked as clinical lead and pharmacovigilance lead in both big pharma and middle/small size pharma. Graduated from Second Military Medical University and University of Maryland

Bonnie Wu, PhD

Vice President

Associate Scientific Director at Janssen Research & Development. Graduated from Peking University and University of Rochester.

Zak Huang, MD

Vice President

Retired regulatory affairs executive, with extensive product development experience for pharmaceuticals, biologics, and medical devices in a setting of either a big Pharma or biotech, plus organizational leadership expertise in building and leading a regulatory team as well as an R&D organization.

Qi Xia, PhD

Vice President & Chief Financial Officer

Experienced lead biostatistician in all stages of oncology clinical trials including solid tumor and hematological malignancy. Graduated from Temple University and University of Southern California.

Wenhui Hu, MD, PhD

Vice President

Professor at Temple University, interested in targeted gene therapy, CRISPR/Cas genome editing, HIV/NeuroHIV cure. Graduated from Peking Union Medical College (PUMC)

Holly Meng, MBA

Vice President

President and CEO of the American Center for Asian Students, and an Advisory Board member of Campus Philly. Graduated from Saint Joseph University

Haitao Hu, PhD

Vice President

Associate Professor at the University of Texas Medical Branch (UTMB), interested in mechanisms of host-virus interactions, antiviral immunity, and development of vaccines and therapeutics. Graduated from the University of Pennsylvania

Jiawei Tang

Vice President

Vice President of Business Strategy at H.L.H, big passionate on health equity, gender equity and environment protection. Graduated from Shenyang Pharmaceutical University

Zijie Feng, PhD

Vice President

Co-founder & Director of technology development in a Biotech company, SidoCel, interested in immunotherapy including CAR T cell therapy and ADC drug to treat solid tumors and leukemia. Graduated from Xiamen University

Xiaoxiao Lu, MD, PhD

Vice President

Director of Real World Value & Evidence at Janssen oncology. Graduated from Tongji Medical College and University of Maryland

Jian Huang, MD, PhD

Vice President

Associate Professor at Coriell Institute for Medical Research, interest in hematopoietic stem cell signal transduction control, fate decision regulation, leukemia drug resistance. Graduated from Peking University Health Science Center and State University of New York Downstate medical center.

Hanghang Zhang, MD, PhD

Vice President

Founder and CEO of NexStage Bi

o, interested in epigenetic therapy, cell and gene therapy, and medical device development. MD, PhD from Lewis Katz School of Medicine at Temple University.

George Li, PhD

Vice President

Founder and CEO of CombiPhos Catalysts, Inc., interested in discovery of Deuterium Drugs, and development of “tailor-made” life-saving deuterium drugs for cancer patients who have “no drug available”. Graduated from Northwestern University.

Feng Roger Luo

Vice President

Chief Development Officer, Head of Clinical and Preclinical Development at Overland Pharmaceuticals. Graduated from North Carolina at Chapel Hill.

Deping Chai, J.D., M.A

Vice President

Partner at Morgan Lewis, prosecuting patent applications in the life sciences, chemistry, and materials science industries. Graduated from Temple University and Peking University.

Xiao Wang, PhD

Vice President

Research Assistant Professor at the University of Pennsylvania, interested in identifying genetic factors related to diseases, and using novel genome-editing tools to develop new therapies. Graduated from Chinese Academy of Sciences.

Xiaodan Ji, PhD

Vice President

Principal Investigator at GSK. Expertise in CHO cell line development, upstream process development and regulatory filing. Graduated from Chinese Academy of Sciences

Kevin He, MBA

Vice President

Director of Business Operations at uBriGene Biosciences, over 15 years of sales and marketing experience in the financial, industry gas, and biotech industries. Graduated from Penn State University

Julia Su, PhD

Vice President

Associate Director of Business Development at WuXi Biologics, focusing on protein/antibody drug discoveries. Graduated from Nanjing University and Louisiana State University

Yichen Zhang, Ph.D, MPH

Director

Senior Manager of Global Health Economics and Outcomes Research at BioMarin Pharmaceutical Inc.. Interested in HEOR, Health Policy research in oncology, rare disease, and chronic disease. Graduated from Tulane University.

Mingyue (Vivian) Li, PhD

Senior Director

Investigator at GSK, interested in research and development of novel therapies. Graduated from the Chinese University of Hong Kong

Xing Liu, Ph.D

Director

Principal Scientist II – R&D at SEED therapeutics. Expertise in molecular glue drug discoveries. Graduated from Chinese Academy of Sciences

Selina Chen, PhD

Director

Scientist at WuxiAppTec, Philadelphia. Expertise in molecular analytical assays. Graduated from University of Science and Technology of China

Long Geng, MS

Director

Lab Manager at Frontage Lab. Expertise in small/ large molecule bioanalysis. Graduated from New Jersey Institute of Technology (NJIT)

Qingchun Lu, MD

Director

Postdoctoral Fellow at Temple University, interested in RNA therapy, cholesterol metabolism, and cancer. Graduated from Sichuan University

Jingyu Luan, PhD, RAC (Senior Director of Global Regulatory Affairs, AstraZeneca, CBA President Elect)

Song Wu, PhD (Head of Translational Medicine, Hansoh Bio/Hansoh Pharm, CBA President)

Hang Lu, MD (Founder and CEO of NextTranslate Biopharmaceutical, Past CBA President)

Dong Shen, PhD (Founder and CEO of RNAimmune, Immediate Past CBA President)

Dajun Yang, PhD (Chairman, CEO, Co-Founder, Ascentage Pharma, Former CBA President)

Patrick Lu, PhD (Founder, Chairman and CEO, Sirnaomics,  Inc. Co-founder of CBA, Former CBA President (2nd).)

Frank Li, PhD (Founder and Senior Consultant, BLA Regulatory, Former CBA President)

Yang Liu, PhD (Founder, Chairman, CEO, and CSO, OncoC4)

Special thanks to our volunteers:

Lisa Tang

Ting Yang